

Date: 5th February, 2019.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Sub.: **Outcome of Board Meeting held on 5th February, 2019.**

Reg.: **Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Dear Sir,

Kindly note that the Audit Committee reviewed and the Board of directors of the Company have approved the unaudited financial results of the Company for the quarter and nine months ended on 31st December, 2018 during their respective meetings held today, i.e. on 5th February, 2019.


The unaudited financial results for the quarter from 1st October, 2018 to 31st December, 2018 duly signed in the format specified under clause 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.

Also enclosed alongwith is the limited audit review report of the auditors of the Company, on the unaudited financial results for the quarter ended on 31st December, 2018.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Ltd.,



(ASHISH SHAH)
Company Secretary.

Encl.: As Stated Above.

Statement of Unaudited Standalone Financial Results for the Nine Months and Third Quarter Ended on 31/12/2018

Rs. In Lacs other than EPS

Sr. No.	Particulars	Quarter Ended			Year to Date		Previous Year Ended
		31/12/2018	30/09/2018	31/12/2017	31/12/2018	31/12/2017	31/03/2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	3227.58	3198.44	3087.44	8751.84	8461.60	11467.42
2	Other Income	66.72	90.48	69.23	247.73	274.59	339.40
3	Total income	3294.30	3288.92	3156.67	8999.57	8736.19	11806.82
4	Expenses						
	(a) Cost of Materials Consumed	475.9	225.53	257.14	950.39	649.26	986.21
	(b) Purchase of Stock-in-trade	653.93	688.03	822.66	1910.70	1670.21	2064.62
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-159.40	77.90	-87.39	-189.68	294.91	348.29
	(d) Employee benefit expenses	794.58	725.58	726.97	2298.66	2095.56	2769.18
	(e) Finance Costs	10.70	9.28	11.10	28.97	28.57	41.21
	(f) Depreciation and Amortisation Expense	35.31	33.21	37.63	100.14	111.81	150.02
	(g) other expenses	825.78	773.12	722.21	2176.27	2223.53	2920.40
	Total Expenses	2636.80	2532.65	2490.32	7275.45	7073.85	9279.93
5	Profit before exceptional items & Tax	657.50	756.27	666.35	1724.12	1662.34	2526.89
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit before tax	657.50	756.27	666.35	1724.12	1662.34	2526.89
8	Tax Expense						
	(i) Current Tax	200.00	195.00	215.00	500.00	515.00	830.00
	(ii) Income Tax for previous years	-4.72	0.00	0.00	-37.52	0.00	14.24
	(ii) Deferred Tax	15.98	-13.11	-2.73	-28.69	-16.10	-38.57
9	Profit after tax for the period	446.24	574.38	454.08	1290.33	1163.44	1721.22
10	Other Comprehensive Income						
	(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	-97.99
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(iii) Items that will be reclassified to profit or loss	8.93	-7.67	6.87	8.79	27.58	27.60
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	-1.52	1.43	0.00	-12.20	0.00	-0.03
11	Total Comprehensive Income for the period	453.65	568.14	460.95	1286.92	1191.02	1650.80
12	Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	458.94	458.94	458.94	458.94
13	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	9.72	12.52	9.89	28.12	25.35	37.50

Notes:

- The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act 2013, read with relevant rules issued there under from 1st April, 2017 and accordingly, these standalone unaudited financial results (including figures for the previous quarters and year ended 31st March, 2018) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS.
- The above statement of unaudited standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 5th February, 2019.




Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127

- 3 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- 4 The figures of the previous year/period have been regrouped/recast/rearranged to render them comparable with figures of the current period.

Place : Mumbai
Date : 05th Febtruary, 2019

By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(ASHISH U BHUTA)
CHAIRMAN AND MANAGING DIRECTOR



 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI -
400034. TEL: 23513758 / 23520330, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Review Report to
The Board of Directors


Jenburkt Pharmaceuticals Ltd.

We have reviewed the accompanying statement of unaudited financial results of Jenburkt Pharmaceuticals Ltd. for the quarter ended 31st December 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D R Mehta & Associates
Chartered Accountants
(FRN. 106207W)



Signature
Ashok Mehta
Partner
(M. No.: 101746)



ASHOK D. MEHTA
M. NO. 101746

Place: Mumbai
Date: 5th February, 2019